This company is no longer active
CRXT.Q Stock Overview
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Clarus Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0011 |
| 52 Week High | US$3.94 |
| 52 Week Low | US$0.001 |
| Beta | 0 |
| 1 Month Change | -92.81% |
| 3 Month Change | -94.63% |
| 1 Year Change | -99.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| CRXT.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -2.4% |
| 1Y | -99.9% | 7.9% | 23.4% |
Return vs Industry: CRXT.Q underperformed the US Pharmaceuticals industry which returned 6% over the past year.
Return vs Market: CRXT.Q underperformed the US Market which returned -10.9% over the past year.
Price Volatility
| CRXT.Q volatility | |
|---|---|
| CRXT.Q Average Weekly Movement | 47.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRXT.Q's share price has been volatile over the past 3 months.
Volatility Over Time: CRXT.Q's weekly volatility has increased from 35% to 48% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 16 | n/a | clarustherapeutics.com |
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.
Clarus Therapeutics Holdings, Inc. Fundamentals Summary
| CRXT.Q fundamental statistics | |
|---|---|
| Market cap | US$57.22k |
| Earnings (TTM) | -US$24.49m |
| Revenue (TTM) | US$16.91m |
0.0x
P/S Ratio0.0x
P/E RatioIs CRXT.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRXT.Q income statement (TTM) | |
|---|---|
| Revenue | US$16.91m |
| Cost of Revenue | US$3.62m |
| Gross Profit | US$13.29m |
| Other Expenses | US$37.77m |
| Earnings | -US$24.49m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 78.58% |
| Net Profit Margin | -144.82% |
| Debt/Equity Ratio | -310.1% |
How did CRXT.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/10 06:01 |
| End of Day Share Price | 2023/02/09 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clarus Therapeutics Holdings, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Jason McCarthy | Maxim Group |
| Nazibur Rahman | Maxim Group |